Patents Examined by John Lucas
  • Patent number: 5648237
    Abstract: Methods for the high yield production of antibody Fv-containing polypeptides, especially Fab' and F(ab').sub.2 antibody fragments are provided. Expression of heavy and light chain Fv in a microbial secretory system is followed by recovery of Fv from the periplasm under conditions that maintain a cysteine residue as a free thiol. The free thiol is reacted with free thiol of an antibody fragment of the same or differing specificity, or with agents such as diagnostic labels or therapeutic moieties. The products offer advantages of homogeneity and purity not available through the use of known methods for preparing such derivatives.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: July 15, 1997
    Assignee: Genentech, Inc.
    Inventor: Paul J. Carter
  • Patent number: 5645817
    Abstract: The present invention describes granulocyte-binding antibody constructs, which were derived from the monoclonal mouse antibody MAk BW 250/183 (EP-A1-0 388 914), as well as a process for their preparation and their use.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 8, 1997
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Gerhard Seemann, Klaus Bosslet
  • Patent number: 5641860
    Abstract: A novel isolated protein which is glycoprotein with 120,000 molecular weight and is expressed on T lymphoblastic lymphoma and leukemia cells, is useful in the diagnosis of T lymphoblastic lymphoma and leukemia.
    Type: Grant
    Filed: May 23, 1994
    Date of Patent: June 24, 1997
    Assignee: Seong Hoe Park
    Inventors: Seong Hoe Park, Young Mee Bae
  • Patent number: 5641865
    Abstract: An interaction system, including an antibody or, antibody fragment having functional capability, which comprises a surfactant-stabilized microheterogeneous dispersion of aqueous phase in a water-immiscible medium, said aqueous phase containing an amount of said antibody or said fragment in a functional state sufficient to effect the interaction; and methods for making and for using said system.
    Type: Grant
    Filed: January 28, 1994
    Date of Patent: June 24, 1997
    Assignee: IGEN, Inc.
    Inventors: Charles N. Durfor, Richard J. Bolin, Allen R. Schantz, II, Richard J. Massey
  • Patent number: 5635356
    Abstract: The present invention relates, in general, to oncoimmunins. In particular, the present invention relates to antibodies that specifically bind to a tumor-derived Oncoimmunin-myeloid (OI-M) factor that induces differentiation of myeloid cells. The invention also provides methods of detecting OI-M factors utilizing OI-M specific antibodies and immunodetection kits.
    Type: Grant
    Filed: March 22, 1994
    Date of Patent: June 3, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Beverly Packard, Akira Komoriya
  • Patent number: 5627034
    Abstract: A method of determining the proliferative status of a carcinoma is disclosed. One obtains a patient sample and then quantitatively analyzes the sample for NGAL gene expression product. The amount of NGAL expression product is compared with a standard curve to determine the S-phase value. The sample can be breast tissue or breast fluid aspirate. Alternatively, blood can by analyzed for this marker to diagnose metastasis.
    Type: Grant
    Filed: December 5, 1995
    Date of Patent: May 6, 1997
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Michael N. Gould, Steven P. Stoesz
  • Patent number: 5605690
    Abstract: A method for treating TNF-dependent inflammatory diseases in a mammal by administering a TNF antagonist, such as soluble TNFR.
    Type: Grant
    Filed: February 8, 1995
    Date of Patent: February 25, 1997
    Assignee: Immunex Corporation
    Inventors: Cindy A. Jacobs, Craig A. Smith
  • Patent number: 5599560
    Abstract: Infusion of neurotrophins, preferably brain-derived neurotrophic factor, are shown to be effective agents for use in the alleviation of symptoms of depression, as demonstrated by reduction of "despair" in the animal forced swim test. Alterations in serotonin levels brought about by neurotrophins suggest use of these factors for the treatment of other disorders caused by defects in serotonin activity.
    Type: Grant
    Filed: November 10, 1994
    Date of Patent: February 4, 1997
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Judith Siuciak
  • Patent number: 5591432
    Abstract: The present invention provides an anti-N-CAM monoclonal antibody which enhances, rather than inhibits, neurite outgrowth both in vitro and in vivo. The antibody has positive regulatory effects on nerve cells of both the central and peripheral nervous systems, and is useful for enhancing neurite outgrowth in m vitro studies and for improving nerve regeneration and repair in vivo.
    Type: Grant
    Filed: March 16, 1995
    Date of Patent: January 7, 1997
    Assignee: Becton, Dickinson and Company
    Inventors: Duane D. Bronson, John J. Hemperly
  • Patent number: 5587161
    Abstract: Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT).
    Type: Grant
    Filed: December 21, 1994
    Date of Patent: December 24, 1996
    Assignees: Zeneca Limited, Cancer Research Campaign Technology Limited
    Inventors: Philip J. Burke, Robert I. Dowell, Anthony B. Mauger, Caroline J. Springer